| scholarly article | Q13442814 |
| P50 | author | Alireza R Rezaie | Q88924052 |
| P2093 | author name string | Hemant Giri | |
| P2860 | cites work | Human myeloid plasma membrane glycoprotein CD13 (gp150) is identical to aminopeptidase N | Q24317442 |
| Syndecan-4 signaling at a glance | Q26865478 | ||
| Structure of beta-antithrombin and the effect of glycosylation on antithrombin's heparin affinity and activity | Q27640482 | ||
| CD300a and CD300f differentially regulate the MyD88 and TRIF-mediated TLR signalling pathways through activation of SHP-1 and/or SHP-2 in human monocytic cell lines | Q28115250 | ||
| Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement | Q28274243 | ||
| IREM-1 is a novel inhibitory receptor expressed by myeloid cells | Q28294075 | ||
| Antiangiogenic activity of the cleaved conformation of the serpin antithrombin | Q33874343 | ||
| A peptide of heparin cofactor II inhibits endotoxin-mediated shock and invasive Pseudomonas aeruginosa infection. | Q33927961 | ||
| Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling | Q34038099 | ||
| Therapeutic rationale for antithrombin III in sepsis | Q34046668 | ||
| Molar antithrombin concentration in normal human plasma | Q34265854 | ||
| Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial | Q34518326 | ||
| Interaction of antithrombin III with bovine aortic segments. Role of heparin in binding and enhanced anticoagulant activity | Q34524635 | ||
| Normal levels of anticoagulant heparan sulfate are not essential for normal hemostasis | Q34889931 | ||
| Antithrombin: a new look at the actions of a serine protease inhibitor | Q35004303 | ||
| CD13 restricts TLR4 endocytic signal transduction in inflammation | Q35472323 | ||
| Proteolytic activation transforms heparin cofactor II into a host defense molecule | Q36914757 | ||
| Mutagenesis studies toward understanding the intracellular signaling mechanism of antithrombin | Q37287790 | ||
| Molecular mechanisms of antithrombin-heparin regulation of blood clotting proteinases. A paradigm for understanding proteinase regulation by serpin family protein proteinase inhibitors. | Q37777806 | ||
| Anticoagulant heparan sulfate to not clot--or not? | Q37784309 | ||
| Partial glycosylation of antithrombin III asparagine-135 is caused by the serine in the third position of its N-glycosylation consensus sequence and is responsible for production of the beta-antithrombin III isoform with enhanced heparin affinity | Q38293560 | ||
| Comparison of biological activities of human antithrombins with high-mannose or complex-type nonfucosylated N-linked oligosaccharides | Q38294435 | ||
| Importance of a 3-O-sulfate group in a heparin pentasaccharide for antithrombotic activity | Q38345840 | ||
| Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. | Q38350190 | ||
| CD300F blocks both MyD88 and TRIF-mediated TLR signaling through activation of Src homology region 2 domain-containing phosphatase 1. | Q39549619 | ||
| Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: antithrombin binding on cultured endothelial cells and perfused rat aorta | Q41197917 | ||
| Antimicrobial effects of helix D-derived peptides of human antithrombin III | Q41747279 | ||
| Helix D elongation and allosteric activation of antithrombin. | Q43821727 | ||
| The serpins: nature's molecular mousetraps | Q45303721 | ||
| High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: efficacy and safety | Q46902575 | ||
| Antithrombin prevents endotoxin-induced pulmonary vascular injury by inhibiting leukocyte activation | Q47851749 | ||
| Antithrombin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study. | Q51076281 | ||
| Antiangiogenic effects of latent antithrombin through perturbed cell-matrix interactions and apoptosis of endothelial cells. | Q52541786 | ||
| Antithrombin up-regulates AMP-activated protein kinase signalling during myocardial ischaemia/reperfusion injury. | Q54321477 | ||
| Anticoagulantly active heparin-like molecules from vascular tissue | Q72814587 | ||
| Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli | Q73426853 | ||
| Antithrombin inhibits lipopolysaccharide-induced tissue factor and interleukin-6 production by mononuclear cells, human umbilical vein endothelial cells, and whole blood | Q73436045 | ||
| Antithrombin III inhibits nuclear factor kappaB activation in human monocytes and vascular endothelial cells | Q74097923 | ||
| Antithrombin III (AT III) prevents LPS-induced pulmonary vascular injury: novel biological activity of AT III | Q74196820 | ||
| Antithrombin reduces ischemia/reperfusion injury of rat liver by increasing the hepatic level of prostacyclin | Q77720659 | ||
| Antiangiogenic antithrombin down-regulates the expression of the proangiogenic heparan sulfate proteoglycan, perlecan, in endothelial cells | Q79175826 | ||
| Syndecan-4-dependent signaling in the inhibition of endotoxin-induced endothelial adherence of neutrophils by antithrombin | Q79339933 | ||
| Local administration of recombinant human antithrombin in a mouse model of peritoneal sepsis | Q80086709 | ||
| A human antithrombin isoform dampens inflammatory responses and protects from organ damage during bacterial infection | Q90243063 | ||
| P433 | issue | 3 | |
| P921 | main subject | anticoagulant | Q215118 |
| P304 | page(s) | 528-533 | |
| P577 | publication date | 2020-03-01 | |
| P1433 | published in | Journal of Thrombosis and Haemostasis | Q6296004 |
| P1476 | title | Antithrombin: An anticoagulant, anti-inflammatory and antibacterial serpin | |
| P478 | volume | 18 |
| Q96028621 | Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research | cites work | P2860 |
Search more.